



Pioneering research. Healthy tomorrow.

Statement from Bharat Biotech International Limited (Bharat), Hyderabad, India on GAVI and its commitments.

Incorporated in 1996 in Hyderabad, India, Bharat was founded by Dr Krishna Ella and his wife Suchitra, with a vision to develop novel vaccines for the developing world.

The company invests in new vaccine development including new and novel manufacturing processes for vaccines such as Hepatitis B vaccine (Cesium chloride- free) — through a proprietary technology. Bharat's Hepatitis B vaccine, Revac-B+, has WHO Pre-Qualification for supply to UN Agencies.

Bharat is focusing on the development and production of vaccines against Malaria, Japanese encephalitis, Rotavirus, Typhoid, Chikungunya and HPV.

We manufacture over 20 product presentations that include vaccines and biopharmaceuticals to supply both private and public markets. Bharat is already supplying its Pentavalent vaccine, ComVac5, to the private market in India and is anticipating WHO PQ for supply to public markets. Bharat's Rotavirus vaccine is entering Phase III clinical trials for efficacy. The commercial strategy for Rotavirus vaccine will be to supply high volumes to GAVI at a lower price range of USD.1.00 to 2.00 per dose.

Bharat recognizes the significant contribution that GAVI has historically made since 2000 in ensuring a stable and reliable market which helped vaccine manufacturers to make investment decisions for sustained supply of vaccine to low income countries. Bharat will continue with its plan to produce affordable low cost vaccines that will tackle some of the main killers of children.

We have deep appreciation of the accomplishments of GAVI as presented at the DCVMN Meet in September 2010 at Hyderabad. As GAVI proposes its third 5-year plan in support of its mission for saving children's lives, we fully endorse GAVI's potential. Bharat looks forward to hearing from the donors how they will continue to support GAVI's potential a reality by making commitments to fund GAVI.

For Bharat Biotech

Dr.G.V.J.A.Harshavardhan

attacenavacken

Director:RVDP September 29, 2010